Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
REGULATORY
First Generics Joining NHI Price List in June Hits Record Low, Bridion is Only Target
MSD’s neuromuscular blocking agent Bridion (sugammadex) was the only brand targeted by generic entries at the latest biannual listing of copycat drugs on June 14, the official gazette revealed. The number of first generics listed and brands targeted both hit…
To read the full story
Related Article
- Bridion Generic Vials Hit Market in Droves at 32% of Originator Price
June 14, 2024
- Bridion Generics Now Available; Maruishi to Launch on May 27
May 23, 2024
- Bridion Sees Rare May Generic Entry for New Dosage Form in Japan
May 21, 2024
- Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
- Japan Approves 1st Generics for 4 APIs towards June Listing, All See AGs
February 16, 2024
REGULATORY
- LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
- MHLW Orders Label Revisions for Epadel, Lotriga, and More
November 15, 2024
- Opposition CDP Eyes Nonpartisan Bill to Scrap Off-Year Drug Price Revisions
November 14, 2024
- MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…